Colistin in critically ill patients

Minerva Anestesiologica

Volumn 79, Issue 2, 2013, Pages 200-208

  Boisson, M ^a,b   Gregoire, N ^a   Couet, W ^a,b   Mimoz, O ^a,b  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Colistin; Gram negative bacteria; Intensive care units; Pharmacokinetics; Pharmacology; Safety

Indexed keywords

CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; IMIPENEM;

ANTIBIOTIC RESISTANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KIDNEY FAILURE; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; NOTE; PSEUDOMEMBRANOUS COLITIS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84876276973     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (52)

1. Flournoy DJ, Reinert RL, Bell-Dixon C, Gentry CA. Increasing antimicrobial resistance in gram-negative bacilli isolated from patients in intensive care units. Am J Infect Control 2000;28:244-50. (Pubitemid 30397521)
2. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
3. Benedict RG, Langlykke AF. Antibiotic activity of Bacillus polymyxa. J Bacteriol 1947;54:24.
4. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999;33:960-7. (Pubitemid 29420995)
5. Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ. Self-assembly behaviour of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B 2010;114:4836-40.
6. Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem 1977;46:723-63. (Pubitemid 8252143)
7. Baines RD Jr, Rifkind D. Intravenous administration of sodium colistimethate. JAMA 1964;190:278-81.
8. Schindler M, Osborn MJ. Intetaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry 1979;18:4425-30. (Pubitemid 10247843)
9. Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J. Bacteriol 1969;97:448-52.
10. Bannatyne RM, Harnett NM, Lee KY, Biggar WD. Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate. J Infect Dis 1977;136:469-74. (Pubitemid 8211377)
11. Mitaka C, Tomita M. Polymyxin B-immobilized fiber column hemoperfusion therapy for septic shock. Shock 2011;36:332-8.
12. Catchpole CR, Andrews JM, Brenwald N, Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997;39:255-60. (Pubitemid 27116423)
13. Clinical and Laboratory Standards Institution. Performance standards for antimicrobial susceptibility testing. Fifteen informational supplement (M100-S15). Wayne, PA, USA: CLSI; 2005.
14. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. EUCAST; 2012. Report No.: 2.0.
15. Clinical and Laboratory Standards Institution. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement (M100-S21). Wayne, PA, USA: CLSI; 2011.
16. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J. Antimicrob. Chemother 2007;59:786-90. (Pubitemid 47073420)
17. Beno P, Krcmery V, Demitrovicova A. Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin. Microbiol Infect 2006;12:497-8.
18. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011;66:2070-4.
19. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother 2008;52:570-3. (Pubitemid 351170830)
20. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008;36:807-11.
21. Champlin FR, Gilleland HE Jr, Conrad RS. Conversion of phospholipids to free fatty acids in response to acquisition of polymyxin resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother 1983;24:5-9. (Pubitemid 13076170)
22. Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002;71:635-700. (Pubitemid 34800232)
23. Hocquet D, Vogne C, El Garch F, Vejux A, Gotoh N, Lee A et al. MexXY-OprM Efflux Pump Is Necessary for Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides. Antimicrob Agents Chemother 2003;47:1371-5. (Pubitemid 36368599)
24. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother 2006;50:2946-50. (Pubitemid 44396396)
25. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Journal of Antimicrobial Chemotherapy 2008;61:636-42. (Pubitemid 351321139)
26. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008;62:1311-8.
27. Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2001;40:117-20. (Pubitemid 32735549)
28. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:905-9. (Pubitemid 36254214)
29. Deris ZZ, Yu HH, Davis K, Soon R, Jacob J, Ku CK et al. The combination of colistin and doripenem combination is synergistic against klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro PK/PD model. Antimicrob Agents Chemother 2012;56:5103-12.
30. Rynn C, Wootton M, Bowker KE, Alan Holt H, Reeves DS. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999;5:32-6. (Pubitemid 29055906)
31. Gobin P, Lemaître F, Marchand S, Couet W, Olivier J-C. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother 2010:54:1941-8.
32. Couet W, Grégoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infection 2012;18:30-9.
33. Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011;89:875-9.
34. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6.
35. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother 2011;55:3284-94.
36. Li J, Rayner CR, Nation RL, Deans R, Boots R, Widdecombe N et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob. Agents Chemother 2005;49:4814-5. (Pubitemid 41552630)
37. Marchand S, Frat J-P, Petitpas F, Lemaître F, Gobin P, Robert R et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 2010;65:1836-7.
38. Athanassa ZE, Markantonis SL, Fousteri M-ZF, Myrianthefs PM, Boutzouka EG, Tsakris A et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 2012;38:1779-86.
39. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006;25:596-9. (Pubitemid 44379694)
40. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005;26:504-7. (Pubitemid 41635502)
41. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011;53:879-84.
42. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr. Pulmonol 2005;39:15-20. (Pubitemid 39628598)
43. Rattanaumpawan P, Lorsutthitham J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 2010;65:2645-9.
44. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006;10:R27.
45. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med 1970;72:857-68.
46. Spapen HD, Honore PM, Gregoire N, Gobin P, de Regt J, Martens GA et al. Convulsions and apnoea in a patient infected with New Delhi metallo-β- lactamase-1 Escherichia coli treated with colistin. J Infect 2011;63:468-70.
47. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin. Microbiol. Infect 2012;8:18-29.
48. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infection 2008;56:432-6.
49. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittell M et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-8. (Pubitemid 36549630)
50. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study. Intensive Care Med 2005;31:1058-65. (Pubitemid 41125336)
51. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010;16(8):1230-6.
52. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin. Infect. Dis 2010;51:1238-44.